biostudies-literatureWu XNatural Science Foundation of Zhejiang ProvinceNational Science Foundation CommitteeThe National Key Technology Research and Development Programme of China, Grant/Award Number: 2022YFC2704200; Key Research and Development Program of Zhejiang Province40-49https://www.ebi.ac.uk/biostudies/studies/S-EPMC10108211biostudies-literatureUnknown129 Suppl 2<h4>Objective</h4>The aim was to assess the expression levels of SLC7A11 and GPX4 in relation to platinum resistance and prognosis in patients with epithelial ovarian cancer (EOC).<h4>Design</h4>A retrospective cohort study.<h4>Setting</h4>Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.<h4>Population or sample</h4>We included 192 eligible patients from hospital between January 2002 and December 2018.<h4>Methods</h4>We retrospectively analysed the medical records of patients with EOC. Surgical specimens of EOC were stained for SLC7A11 and GPX4. Survival analysis was performed using the Kaplan-Meier and Cox regression methods.<h4>Main outcome measures</h4>Clinical end points include platinum-free interval (PFI), progression-free survival (PFS) and overall survival BJOG : an international journal of obstetrics and gynaecologyHigh co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer.PMC10108211821035052019C0301082171939LQ20H300002Fan FZhang TQin JFei WShen TShen SGu JCheng XWu XfalseHigh co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer.<h4>Objective</h4>The aim was to assess the expression levels of SLC7A11 and GPX4 in relation to platinum resistance and prognosis in patients with epithelial ovarian cancer (EOC).<h4>Design</h4>A retrospective cohort study.<h4>Setting</h4>Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.<h4>Population or sample</h4>We included 192 eligible patients from hospital between January 2002 and December 2018.<h4>Methods</h4>We retrospectively analysed the medical records of patients with EOC. Surgical specimens of EOC were stained for SLC7A11 and GPX4. Survival analysis was performed using the Kaplan-Meier and Cox regression methods.<h4>Main outcome measures</h4>Clinical end points include platinum-free interval (PFI), progression-free survival (PFS) and overall survival 2022-01-01T00:00:00Z2022 Nov2025-04-26T05:01:55.366Z2025-04-06T11:21:13.528ZS-EPMC101082113648506910.1111/1471-0528.17327